Old phenothiazine and dibenzothiadiazepine derivatives for tomorrow's neuroprotective therapies against neurodegenerative diseases

European Journal of Medicinal Chemistry

Volumn 45, Issue 12, 2010, Pages 6152-6158

  González Muñoz, Gema C ^a   Arce, Mariana P ^a   López, Beatriz ^a   Pérez, Concepción ^a   Villarroya, Mercedes ^b,c   López, Manuela G ^b,c,d   García, Antonio G ^b,c,e   Conde, Santiago ^a   Rodríguez Franco, María Isabel ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b INSTITUTO TEÓFILO HERNANDO   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Butyrylcholinesterase inhibition; Dibenzothiadiazepines; Neuroprotection; Oxidative stress; Phenothiazines

Indexed keywords

1,1' (4 CHLORODIBENZO[B,F][1,4,5]THIADIAZEPINE 5,6 DIYL)DIETHANONE; 10H PHENOTHIAZIN 10 AMINE; BENZOTHIADIAZINE DERIVATIVE; CHOLINESTERASE; DIBENZOTHIADIAZEPINE DERIVATIVE; N (2 CHLORO 10H PHENOTHIAZIN 10 YL)ACETAMIDE; N (3 CHLORO 10H PHENOTHIAZIN 10 YL) 2 (4 METHYLPIPERAZIN 1 YL)ACETAMIDE; N (3 CHLORO 10H PHENOTHIAZIN 10 YL) 3 (DIMETHYLAMINO)PROPANAMIDE; N [2 (10H PHENOTHIAZIN 10 YL)ETHYL] 4 METHYLPIPERAZIN 1 AMINE; PHENOTHIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; DEGENERATIVE DISEASE; DRUG ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; NEUROPROTECTION; OXIDATIVE STRESS;

EID: 78649318169     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2010.09.039     Document Type: Article

References (40)

1. P. Coleman, H. Federoff, and R. Kurlan A focus on the synapse for neuroprotection in Alzheimer disease and other dementias Neurology 63 2004 1155 1162
2. V.P. Reddy, X. Zhu, G. Perry, and M.A. Smith Oxidative stress in diabetes and Alzheimer's disease J. Alzheimers Dis. 16 2009 763 774
3. A.V. Terry, and J.J. Buccafusco The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development J. Pharmacol. Exp. Ther. 306 2003 821 827
4. R.M. Lane, S.G. Potkin, and A. Enz Targeting acetylcholinesterase and butyrylcholinesterase in dementia Int. J. Neuropsychopharmacol. 9 2006 101 124
5. N.H. Greig, T. Utsuki, Q. Yu, X. Zhu, H.W. Holloway, T. Perry, B. Lee, D.K. Ingram, and D.K. Lahiri A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase Curr. Med. Res. Opin. 17 2001 159 165
6. M.L. Bolognesi, M. Rosini, V. Andrisano, M. Bartolini, A. Minarini, V. Tumiatti, and C. Melchiorre MTDL design strategy in the context of Alzheimer's disease: from lipocrine to memoquin and beyond Curr. Pharm. Des. 15 2009 601 613
7. L. Fang, D. Appenroth, M. Decker, M. Kiehntopf, C. Roegler, T. Deufel, C. Fleck, S. Peng, Y. Zhang, and J. Lehmann Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates J. Med. Chem. 51 2008 713 716
8. R. Morphy, and Z. Rankovic Designed multiple ligands. An emerging drug discovery paradigm J. Med. Chem. 48 2005 6523 6543
9. M.I. Fernández-Bachiller, C. Pérez, G.C. González-Muñoz, S. Conde, M.G. López, M. Villarroya, A.G. García, and M.I. Rodríguez-Franco Novel tacrine - 8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties J. Med. Chem. 53 2010 4927 4937
10. M.P. Arce, M.I. Rodríguez-Franco, G.C. González- Muñoz, C. Pérez, B. López, M. Villarroya, M.G. López, A.G. García, and S. Conde Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease J. Med. Chem. 52 2009 7249 7257
11. M.I. Fernández-Bachiller, C. Pérez, N.E. Campillo, J.A. Páez, G.C. González-Muñoz, P. Usán, E. García-Palomero, M.G. López, M. Villarroya, A.G. García, A. Martínez, and M.I. Rodríguez-Franco Tacrine - melatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties Chem. Med. Chem. 4 2009 828 841
12. M.I. Rodríguez-Franco, M.I. Fernández-Bachiller, C. Pérez, B. Hernández-Ledesma, and B. Bartolomé Novel tacrine - melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties J. Med. Chem. 49 2006 459 462
13. C. Spuch, D. Antequera, M.I. Fernández-Bachiller, M.I. Rodríguez-Franco, and E. Carro A new tacrine - melatonin hybrid reduces amyloid burden and behavioral deficits in a mouse model of Alzheimer's disease Neurotox. Res. 17 2010 421 431
14. S. Conde, A. Martínez, D.I. Pérez, C. Pérez, and F.J. Moreno Thienyl and phenyl alpha-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3beta) from a library of compound searching J. Med. Chem. 46 2003 4631 4633
15. D.I. Pérez, S. Conde, C. Pérez, C. Gil, D. Simon, F. Wandosell, F.J. Moreno, J.L. Gelpí, F.J. Luque, and A. Martínez Thienylhalomethylketones: irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools Bioorg. Med. Chem. 17 2009 6914 6925
16. S. Darvesh, R.S. McDonald, K.V. Darvesh, D. Mataija, S. Conrad, G. Gomez, R. Walsh, and E. Martin Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine Bioorg. Med. Chem. 15 2007 6367 6378
17. S. Darvesh, K.V. Darvesh, R.S. McDonald, D. Mataija, R. Walsh, S. Mothana, O. Lockridge, and E. Martin Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase J. Med. Chem. 51 2008 4200 4212
18. S. Darvesh, I.R. Pottie, K.V. Darvesh, R.S. McDonald, R. Walsh, S. Conrad, A. Penwell, D. Mataija, and E. Martin Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants Bioorg. Med. Chem. 18 2010 2232 2244
19. A. Appert-Colin, N. Callizot, Use of piperazine phenothiazine derivatives in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on CNS and/or PNS, Eur. Pat. EP1,470,818, 2004.
20. C.M. Wischik, P.C. Edwards, R.Y. Lai, M. Roth, and C.R. Harrington Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines Proc. Natl. Acad. Sci. U.S.A. 93 1996 11213 11218
21. S. Deiana, C.R. Harrington, C.M. Wischik, and G. Riedel Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine Psychopharmacology 202 2009 53 65
22. C. Corral, J. Lissavetzky, and R. Madroñero Analogues of antipsychotic phenothiazines 10-(2- N', N'-disubstituted hydrazinoethyl) phenothiazines Eur. J. Med. Chem. 4 1978 389 391
23. C. Corral, J. Lissavetzky, Procedimiento de preparación de 10-(γ-dialquilamino)propilamino fenotiazinas, Spanish Patent ES472157, 1978.
24. C. Corral, J. Lissavetzky, and G. Quintanilla Synthesis of 10-aminophenothiazines and derivatives J. Heterocycl. Chem. 15 1978 1137 1140
25. C. Corral, J. Lissavetzky, and G. Quintanilla New method for the synthesis of chloro-substituted dibenzo[b,f][1,4,5]thiadiazepines and their 5,6-dihydro derivatives J. Org. Chem. 47 1982 2214 2215
26. G.L. Ellman, K.D. Courtney, V. Andres Jr., and R.M. Feather-Stone A new and rapid colorimetric determination of acetylcholinesterase activity Biochem. Pharmacol. 7 1961 88 95
27. N. Greig, T. Utsuki, D. Ingram, Y. Wang, G. Pepeu, C. Scali, Q. Yu, J. Mamczarz, H. Holloway, T. Giordano, D. Chen, K. Furukawa, K. Sambamurti, A. Brossi, and D. Lahiri Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent Proc. Natl. Acad. Sci. U.S.A. 102 2005 17213 17218
28. I. Manoharan, A. Kuznetsova, J.D. Fisk, R. Boopathy, O. Lockridge, and S. Darvesh Comparison of cognitive functions between people with silent and wild-type butyrylcholinesterase J. Neural Transm. 114 2007 939 945
29. 2+ oscillations induced by veratridine Eur. J. Pharmacol. 270 1994 331 339
30. K. Newhouse, S.L. Hsuan, S.H. Chang, B. Cai, Y. Wang, and Z. Xia Rotenone-induced apoptosis is mediated by p38 and JNK MAP kinases in human dopaminergic SH-SY5Y cells Toxicol. Sci. 79 2004 137 146
31. E. Arias, E. Alés, N.H. Gabilán, M.F. Cano-Abad, M. Villarroya, A.G. García, and M.G. López Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors Neuropharmacology 46 2004 103 114
32. E. Arias, S. Gallego-Sandín, M. Villarroya, A.G. García, and M.G. López Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors J. Pharmacol. Exp. Ther. 315 2005 1346 1353
33. C. Orozco, C. de los Ríos, E. Arias, R. León, A.G. García, J.L. Marco, M. Villarroya, and M.G. López ITH4012, a novel acetylcholinesterase inhibitor with "calcium promoter" and neuroprotective properties J. Pharmacol. Exp. Ther. 310 2004 987 994
34. I.A. Castro, M.M. Rogero, R.M. Junqueira, and M.M. Carrapeiro Free radical scavenger and antioxidant capacity correlation of alpha-tocopherol and trolox measured by three in vitro methodologies Int. J. Food Sci. Nutr. 57 2006 75 82
35. L. Di, E.H. Kerns, K. Fan, O.J. McConnell, and G.T. Carter High throughput artificial membrane permeability assay for blood-brain barrier Eur. J. Med. Chem. 38 2003 223 232
36. J. Marco-Contelles, R. León, C. de los Ríos, A. Samadi, M. Bartolini, V. Andrisano, O. Huertas, X. Barril, F.J. Luque, M.I. Rodríguez-Franco, B. López, M.G. López, A.G. García, M.C. Carreiras, and M. Villarroya Tacripyrines, the first tacrine- dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease J. Med. Chem. 52 2009 2724 2732
37. P. Camps, X. Formosa, C. Galdeano, D. Muñoz-Torrero, L. Ramírez, E. Gómez, N. Isambert, R. Lavilla, A. Badía, M.V. Clos, M. Bartolini, F. Mancini, V. Andrisano, M.P. Arce, M.I. Rodríguez-Franco, O. Huertas, T. Dafni, and F.J. Luque Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds J. Med. Chem. 52 2009 5365 5379
38. Compound 3 was not described before. It might be obtained following the protocols described in references [22] and [25].
39. C.P. LeBel, H. Ischiropoulos, and S.C. Bondy Evaluation of the probe 2′,7′ dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress Chem. Res. Toxicol. 5 1992 227 231
40. A. Negre-Salvayre, N. Auge, C. Duval, F. Robbesyn, J.C. Thiers, D. Nazzal, H. Benoist, and R. Salvayre Detection of intracellular reactive oxygen species in cultured cells using fluorescent probes Methods Enzymol. 352 2002 62 71